The initial agenda and speaker lineup is now available for San Diego’s Xcelerating Life Sciences event on March 18 at Takeda Research in California. Join Xconomy as we bring together local innovators, entrepreneurs, and investors to explore bold new ideas in... Read more »
Two privately held biotechs on Tuesday announced plans for reverse mergers, transactions that provide a faster route to go public than a conventional IPO and also give struggling public companies a chance to recoup some value for their shareholders.
San Diego... Read more »
Sotatercept was one of the first compounds to emerge from the labs of Acceleron Pharma, but it became a forgotten piece of the company’s pipeline. Passed over as a candidate to treat a rare blood disorder and stalled in tests in... Read more »
Subtle changes can presage a worsening of a chronic condition, but symptoms may not become apparent to a patient until it’s time to call an ambulance.
BioIntelliSense, a Denver-based digital health startup, has developed a wearable sensor meant to monitor patients’... Read more »
Biopharmaceutical companies focused on advanced therapies are changing industry R&D, manufacturing, and supply chain models according to KPMG.
The audit, tax, and advisory services firm shared details of the trend in its Healthcare & Life Sciences Outlook report, explaining that for... Read more »
So far this year four privately held companies have made the transition to trading on the public markets.
By month’s end, five more are anticipated to join the class of 2020 initial public offerings—and four of those are in life sciences,... Read more »
Company news slowed somewhat this week, perhaps as some took the federal Martin Luther King Jr. Day holiday away from the office and others recovered from back-to-back meetings and late nights at the JP Morgan Healthcare Conference. However, a new coronavirus... Read more »
Talking about sex with potential investors? For EvoFem Biosciences CEO Saundra Pelletier, it’s the first item on the docket.
Her company recently submitted Amphora, a non-hormonal contraceptive gel, to the FDA for review. EvoFem (NASDAQ: EVFM)—and the rest of the... Read more »
Halozyme suffered a setback in November when its investigational pancreatic drug failed a Phase 3 clinical trial, but its CEO says the biotech’s drug delivery technology will make the company profitable as early as the second quarter of this year.... Read more »
Perhaps the most talked-about news at the JP Morgan Healthcare Conference this week was a new startup that launched with $200 million and an ambitious claim that its first drug would be approved within five years, and 10 in total within... Read more »
We’re excited to announce the first in Xconomy’s new Xcelerating Life Sciences event series convening local communities of innovators, executives, rising pioneers, entrepreneurs, investors, and scientists: Xcelerating Life Sciences San Diego will help you stay at the forefront of San Diego’s... Read more »
[Updated 1/15/2020, 8:51 a.m. See below.] As the nation grapples with the ongoing opioid crisis, an FDA advisory panel on Tuesday unanimously voted against recommending approval of a Nektar Therapeutics painkiller that would add a new compound to the... Read more »
Daré Bioscience launched in 2015 with the aim of assembling a portfolio of novel women’s health products intended to pique interest from major pharmaceutical companies.
Now the San Diego-based company has inked its first deal with Big Pharma, signing an agreement... Read more »